EUVIMEDEUVIMED entdecken
StudienprotokollOpen Access · CC BY 4.0

Evaluating elexacaftor/tezacaftor/ivacaftor (ETI; Trikafta™) for treatment of patients with non-cystic fibrosis bronchiectasis (NCFBE): A clinical study protocol

Colin E Swenson, William R Hunt, Candela Manfredi, Diana J Beltran, Jeong S Hong, Brian R Davis, Shingo Suzuki, Cristina Barillá, Andras Rab, Cynthia Chico, Joy Dangerfield, Ashleigh Streby und 6 weitere

PLOS ONE · 2025

DOI: 10.1371/journal.pone.0316721 ↗

Kurz gefasst

Studienprotokoll in der Zeitschrift PLOS ONE, 2025. Verfasst von Colin E Swenson und 17 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pulmonology, Allergy, Critical Care and Sleep Medicine, Department of Medicine, Emory University School of Medicine, Atlanta, GA, United …. Hauptthemen laut MEDLINE: Aminophenols, Quinolones, Benzodioxoles, Bronchiectasis. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Marcus Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Non-cystic fibrosis bronchiectasis (NCFBE) is a disease that exhibits dilatation of airways, airflow obstruction, persistent cough, excessive sputum production, and refractory respiratory infections. NCFBE exhibits clinical and pathological manifestations similar to key features of cystic fibrosis (CF) lung disease. In CF, pathogenesis results from dysfunction of the cystic fibrosis transmembrane conductance regulator (CFTR), and diagnosis is made by demonstrating elevated sweat chloride concentrations (typically ≥60 mEq/L), two CFTR mutations known to be causal, multi-organ tissue injury, or combination(s) of these findings.

Objective

Based on a considerable body of evidence, we believe many patients with NCFBE have disease likely to benefit from drugs such as elexacaftor/tezacaftor/ivacaftor (ETI) that activate CFTR-dependent ion transport. ETI is currently prescribed solely for treatment of CF and has not been adequately tested or proposed for patients with NCFBE, many of whom exhibit decreased CFTR function. Accordingly, we are conducting a clinical trial of ETI in subjects carrying a diagnosis of NCFBE.

Methods

Participants will exhibit one disease-causing CFTR mutation and/or sweat chloride measurements of 30–59 mEq/L. Cutaneous punch biopsy or blood samples will be obtained for iPS cell differentiation into airway epithelial monolayers–which will then be tested for response to ETI. Each patient will be given CFTR modulator treatment for approximately four weeks, with monitoring of clinical endpoints that include FEV 1 (forced expiratory volume in one second), sweat chloride, quality of life questionnaire, and weight. The study will evaluate response of patients with NCFBE to ETI, and test usefulness of iPSC-derived airway epithelial monolayers as a novel in vitro technology for predicting clinical benefit.

Trial registration

This trial is registered at clinicaltrials.gov (Identifier: NCT05743946 . Date: 02/23/2023).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AminophenolsQuinolonesBenzodioxolesBronchiectasisPyrazolesIndolesPyridinesPyrrolidinesHumansDrug CombinationsCystic Fibrosis Transmembrane Conductance RegulatorMaleFemaleAdultCystic FibrosisMiddle AgedTreatment OutcomeChloride Channel AgonistsQuinolines

Substanzen

AminophenolsQuinolonesBenzodioxolesDrug CombinationsPyrazolesCystic Fibrosis Transmembrane Conductance RegulatorIndolesPyridinesivacaftorPyrrolidines

Autor:innen und Institutionen

  • Division of Pulmonology, Allergy, Critical Care and Sleep Medicine, Department of Medicine, Emory University School of Medicine, Atlanta, GA, United States of America.
  • Division of Pulmonary, Asthma, Cystic Fibrosis and Sleep, Department of Pediatrics, Emory University School of Medicine and Children's Healthcare of Atlanta, Atlanta, GA, United States of America.
  • Georgia Clinical & Translational Science Alliance, Emory University, Atlanta, GA, United States of America.
  • Division of Pulmonary, Allergy & Critical Care Medicine, University of Alabama at Birmingham Heersink School of Medicine, Birmingham, AL, United States of America.

ORCID-Profile: Eric J Sorscher

Förderung

  • Marcus Foundation

Zitieren

APA

Swenson, C. E., Hunt, W. R., Manfredi, C., Beltran, D. J., Hong, J. S., Davis, B. R., Suzuki, S., Barillá, C., Rab, A., Chico, C., Dangerfield, J., Streby, A., Barton, E., Cox, E. M., Stecenko, A. A., Westbrook, A., Kapolka, R., & Sorscher, E. J. (2025). Evaluating elexacaftor/tezacaftor/ivacaftor (ETI; Trikafta™) for treatment of patients with non-cystic fibrosis bronchiectasis (NCFBE): A clinical study protocol. PLOS ONE. https://doi.org/10.1371/journal.pone.0316721

Vancouver

Swenson CE, Hunt WR, Manfredi C, Beltran DJ, Hong JS, Davis BR, et al. Evaluating elexacaftor/tezacaftor/ivacaftor (ETI; Trikafta™) for treatment of patients with non-cystic fibrosis bronchiectasis (NCFBE): A clinical study protocol. PLOS ONE. 2025. doi:10.1371/journal.pone.0316721

BibTeX
@article{Swenson2025,
  author = {Swenson, Colin E and Hunt, William R and Manfredi, Candela and Beltran, Diana J and Hong, Jeong S and Davis, Brian R and Suzuki, Shingo and Barillá, Cristina and Rab, Andras and Chico, Cynthia and Dangerfield, Joy and Streby, Ashleigh and Barton, Erin and Cox, Elizabeth M and Stecenko, Arlene A and Westbrook, Adrianna and Kapolka, Rebecca and Sorscher, Eric J},
  title = {Evaluating elexacaftor/tezacaftor/ivacaftor (ETI; Trikafta™) for treatment of patients with non-cystic fibrosis bronchiectasis (NCFBE): A clinical study protocol},
  journal = {PLOS ONE},
  year = {2025},
  doi = {10.1371/journal.pone.0316721}
}
Kostenlos starten →